PATENT CLAIM ANALYSIS

Application Number: 16364653
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "356000"]

Abstract:
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Claim (Index 1):
A method of treating schizophrenia, the method comprising administering to a human individual in need thereof a therapeutically effective amount of a RXR agonist and a thyroid hormone, wherein administration of the combination of the RXR agonist and the thyroid hormone treats the schizophrenia in the individual, wherein the RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, and has the structure of formula III: and wherein the combination of RXR agonist and thyroid hormone causes a greater improvement in the schizophrenia than the RXR agonist or thyroid hormone alone.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.1875
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16296012', '16118001', '15339762', '15812821', '15339752']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8875937795828407
- 35 USC 102 Novelty (BERT): 0.7220894062908286
- Combined Prediction Score: 0.8710433422536396
- Mean Citation Score: 769.5742280000003
- Max Citation Score: 792.946
- Similarity Product: 757.5082404772045

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test